NIH Partners with UMB to Develop Ketamine Metabolite for Depression Treatment

Summary

The National Institute of Aging (NIA), National Institute of Mental Health (NIMH), and National Center for Advancing Translational Sciences (NCATS) at the National Institutes of Health (NIH) are collaborating with the University of Maryland at Baltimore (UMB) to seek CRADA partners for the development of ketamine metabolite (2R, 6R-HNK) to treat depression and anxiety disorders.